H.C. Wainwright analyst Robert Burns reiterated a Buy rating on PMV Pharmaceuticals today and set a price target of $5.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors surrounding PMV Pharmaceuticals’ recent developments. The updated data from the Phase 2 PYNNACLE trial for rezatapopt in ovarian cancer shows promising results, with a 46% overall response rate in the ovarian cancer cohort, which is competitive with other treatments like Elahere and relacorilant. This positions rezatapopt as a strong candidate for a New Drug Application filing, particularly given the challenging prognosis for TP53 Y220C-mutated ovarian cancer patients.
Furthermore, PMV Pharmaceuticals has outlined a clear plan to enroll additional patients and expects to submit an NDA by the end of the first quarter of 2027. This strategic approach, coupled with the promising trial data, supports the potential for significant advancements in treatment options for ovarian cancer. These factors contribute to the reiteration of the Buy rating and a 12-month price target of $5 per share.